Combination immunotherapy improves survival in mesothelioma – European Pharmaceutical Review
European Pharmaceutical Review |
Combination immunotherapy improves survival in mesothelioma
European Pharmaceutical Review Combined treatment with two cancer immunotherapy drugs – one a novel immune modulator and one that focuses and activates the antitumor immune response – significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma. Lymphocytes armed to kill: how customised cell engineering … Strategic Analysis of Global Cancer Immunotherapy Market … |
